{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T02:00:37Z","timestamp":1794621637228,"version":"4.9.1"},"reference-count":195,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,12]],"date-time":"2023-07-12T00:00:00Z","timestamp":1689120000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Nuclear Medicine"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1053\/j.semnuclmed.2023.07.004","type":"journal-article","created":{"date-parts":[[2023,8,17]],"date-time":"2023-08-17T02:23:12Z","timestamp":1692238992000},"page":"97-118","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":48,"title":["Bone Metastasis in Prostate Cancer: Bone Scan Versus PET Imaging"],"prefix":"10.1053","volume":"54","author":[{"given":"Nasibeh","family":"Mohseninia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nazanin","family":"Zamani-Siahkali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Harsini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghasemali","family":"Divband","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Pirich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohsen","family":"Beheshti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.semnuclmed.2023.07.004_bib0001","first-page":"451","article-title":"Global cancer statistics 2022: The trends projection analysis","volume":"10","author":"Chhikara","year":"2023","journal-title":"Chem Biol Lett"},{"key":"10.1053\/j.semnuclmed.2023.07.004_bib0002","doi-asserted-by":"crossref","first-page":"e44","DOI":"10.1097\/RLU.0000000000000993","article-title":"Molecular and functional imaging of bone metastases in breast and prostate cancers: An overview","volume":"41","author":"Azad","year":"2016","journal-title":"Clin Nucl Med"},{"key":"10.1053\/j.semnuclmed.2023.07.004_bib0003","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1053\/hp.2000.6698","article-title":"Metastatic patterns of prostate cancer: An autopsy study of 1,589 patients","volume":"31","author":"Bubendorf","year":"2000","journal-title":"Hum Pathol"},{"key":"10.1053\/j.semnuclmed.2023.07.004_bib0004","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/978-3-030-32656-2_9","article-title":"The bone microenvironment in prostate cancer metastasis","volume":"31","author":"DiNatale","year":"2019","journal-title":"Adv Exp Med Biol"},{"key":"10.1053\/j.semnuclmed.2023.07.004_bib0005","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s12885-017-3922-0","article-title":"Incidence of bone metastases in patients with solid tumors: Analysis of oncology electronic medical records in the United States","volume":"18","author":"Hernandez","year":"2018","journal-title":"BMC Cancer"},{"key":"10.1053\/j.semnuclmed.2023.07.004_bib0006","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1016\/j.annonc.2020.07.019","article-title":"Bone health in cancer: ESMO clinical practice guidelines","volume":"31","author":"Coleman","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1053\/j.semnuclmed.2023.07.004_bib0007","doi-asserted-by":"crossref","DOI":"10.1016\/j.canep.2019.101628","article-title":"Identifying skeletal-related events for prostate cancer patients in routinely collected hospital data","volume":"63","author":"Parry","year":"2019","journal-title":"Cancer Epidemiol"},{"key":"10.1053\/j.semnuclmed.2023.07.004_bib0008","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1158\/1535-7163.MCT-07-0234","article-title":"Molecular biology of bone metastasis","volume":"6","author":"Kingsley","year":"2007","journal-title":"Mol Cancer Ther"},{"key":"10.1053\/j.semnuclmed.2023.07.004_bib0009","doi-asserted-by":"crossref","first-page":"789","DOI":"10.3171\/2010.6.SPINE10167","article-title":"Predictors of survival in patients with prostate cancer and spinal metastasis: Presented at the 2009 Joint Spine Section Meeting","volume":"13","author":"Drzymalski","year":"2010","journal-title":"J Neurosurg Spine"},{"key":"10.1053\/j.semnuclmed.2023.07.004_bib0010","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2016-000037","article-title":"Diagnosis and treatment of bone metastasis: Comprehensive guideline of the Japanese Society of Medical Oncology, Japanese orthopedic association, Japanese Urological Association, and Japanese Society for Radiation Oncology","volume":"1","author":"Shibata","year":"2016","journal-title":"ESMO Open"},{"key":"10.1053\/j.semnuclmed.2023.07.004_bib0011","article-title":"EAU, EANM, ESTRO, ESUR, ISUP, SIOG guidlines on prostate cancer","author":"Mottet","year":"2023","journal-title":"EAU guidlines, Edn, presented at the EAU Annual Congress Milan"},{"key":"10.1053\/j.semnuclmed.2023.07.004_bib0012","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1200\/JCO.19.02757","article-title":"Optimum imaging strategies for advanced prostate cancer: ASCO guideline","volume":"38","author":"Trabulsi","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2023.07.004_bib0013","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1148\/rg.232025103","article-title":"Radionuclide bone imaging: An illustrative review","volume":"23","author":"Love","year":"2003","journal-title":"Radiographics"},{"key":"10.1053\/j.semnuclmed.2023.07.004_bib0014","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1053\/j.semnuclmed.2016.07.003","article-title":"(18)F-NaF-PET\/CT and (99m)Tc-MDP bone scintigraphy in the detection of bone metastases in prostate cancer","volume":"46","author":"Langsteger","year":"2016","journal-title":"Semin Nucl Med"},{"key":"10.1053\/j.semnuclmed.2023.07.004_bib0015","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1038\/s41416-018-0323-3","article-title":"North American population-based validation of the National Comprehensive Cancer Network Practice Guideline Recommendations for locoregional lymph node and bone imaging in prostate cancer patients","volume":"119","author":"Preisser","year":"2018","journal-title":"Br J Cancer"},{"key":"10.1053\/j.semnuclmed.2023.07.004_bib0016","doi-asserted-by":"crossref","first-page":"59","DOI":"10.3109\/0284186X.2015.1027411","article-title":"Prospective evaluation of planar bone scintigraphy, SPECT, SPECT\/CT, 18F-NaF PET\/CT and whole body 1.5 T MRI, including DWI, for the detection of bone metastases in high risk breast and prostate cancer patients: SKELETA clinical trial","volume":"55","author":"Jambor","year":"2016","journal-title":"Acta Oncol"},{"key":"10.1053\/j.semnuclmed.2023.07.004_bib0017","doi-asserted-by":"crossref","first-page":"W467","DOI":"10.2214\/AJR.06.1215","article-title":"Characterization of focal bone lesions in the axial skeleton: Performance of planar bone scintigraphy compared with SPECT and SPECT fused with CT","volume":"188","author":"Strobel","year":"2007","journal-title":"AJR Am J Roentgenol"},{"key":"10.1053\/j.semnuclmed.2023.07.004_bib0018","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.3390\/biomedicines10102533","article-title":"The performance of FDA-approved?PET imaging agents in the detection of prostate cancer","volume":"10","author":"Li","year":"2022","journal-title":"Biomedicines"},{"key":"10.1053\/j.semnuclmed.2023.07.004_bib0019","first-page":"142","article-title":"Molecular imaging of prostate cancer","volume":"36","author":"Wibmer","year":"2016","journal-title":"Br J Radiol"},{"key":"10.1053\/j.semnuclmed.2023.07.004_bib0020","first-page":"11","article-title":"The bone scan. in Seminars in nuclear medicine. Elsevier","volume":"42","author":"Brenner","year":"2012","journal-title":"WB Saunders; Philadelphia, Pennsylvania"},{"key":"10.1053\/j.semnuclmed.2023.07.004_bib0021","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1053\/j.semnuclmed.2015.02.002","article-title":"Pitfalls and limitations of radionuclide planar and hybrid bone imaging","volume":"45","author":"Agrawal","year":"2015","journal-title":"Sem Nucl Med"},{"key":"10.1053\/j.semnuclmed.2023.07.004_bib0022","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1007\/s00256-019-03230-z","article-title":"Comparison of PSMA-PET\/CT, choline-PET\/CT, NaF-PET\/CT, MRI, and bone scintigraphy in the diagnosis of bone metastases in patients with prostate cancer: A systematic review and meta-analysis","volume":"48","author":"Zhou","year":"2019","journal-title":"Skeletal Radiol"},{"key":"10.1053\/j.semnuclmed.2023.07.004_bib0023","first-page":"53","article-title":"Integration of bone and computed tomography scans to assess bone metastasis in metastatic castration-resistant prostate cancer","volume":"15","author":"Parker","year":"2017","journal-title":"Skeletal Radiol"},{"key":"10.1053\/j.semnuclmed.2023.07.004_bib0024","doi-asserted-by":"crossref","first-page":"e25417","DOI":"10.1097\/MD.0000000000025417","article-title":"The meta-analysis of the effect of 68Ga-PSMA-PET\/CT diagnosis of prostatic cancer compared with bone scan","volume":"100","author":"Zhao","year":"2021","journal-title":"Medicine (Baltimore)"},{"key":"10.1053\/j.semnuclmed.2023.07.004_bib0025","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.eururo.2023.03.001","volume":"84","author":"Chow","year":"2023","journal-title":"Eur Urol"},{"key":"10.1053\/j.semnuclmed.2023.07.004_bib0026","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1007\/s12149-020-01474-7","article-title":"Does bone scintigraphy still have a role in the era of 68 Ga-PSMA PET\/CT in prostate cancer?","volume":"34","author":"Simsek","year":"2020","journal-title":"Ann Nucl Med"},{"key":"10.1053\/j.semnuclmed.2023.07.004_bib0027","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1007\/s00259-008-0721-5","article-title":"Quality of planar whole-body bone scan interpretations: A nationwide survey","volume":"35","author":"Sadik","year":"2008","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2023.07.004_bib0028","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1007\/BF00168159","article-title":"The reliability of the 3-phase bone scan in suspected scaphoid fracture: An inter-and intraobserver variability analysis","volume":"19","author":"Tiel-van Buul","year":"1992","journal-title":"Eur J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2023.07.004_bib0029","first-page":"1765","article-title":"A new parameter for measuring metastatic bone involvement by prostate cancer: The Bone Scan Index","volume":"4","author":"Imbriaco","year":"1998","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.semnuclmed.2023.07.004_bib0030","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.3390\/cancers12092654","article-title":"Analysis of bone scans in various tumor entities using a deep-learning-based artificial neural network algorithm: Evaluation of diagnostic performance","volume":"12","author":"Wuestemann","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1053\/j.semnuclmed.2023.07.004_bib0031","doi-asserted-by":"crossref","first-page":"84449","DOI":"10.18632\/oncotarget.19680","article-title":"Prognostic value of bone scan index as an imaging biomarker in metastatic prostate cancer: A meta-analysis","volume":"8","author":"Li","year":"2017","journal-title":"Oncotarget"},{"key":"10.1053\/j.semnuclmed.2023.07.004_bib0032","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.eururo.2012.01.037","article-title":"A novel automated platform for quantifying the extent of skeletal tumour involvement in prostate cancer patients using the Bone Scan Index","volume":"62","author":"Ulmert","year":"2012","journal-title":"Eur Urol"},{"key":"10.1053\/j.semnuclmed.2023.07.004_bib0033","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/2191-219X-3-64","article-title":"Progression of bone metastases in patients with prostate cancer-automated detection of new lesions and calculation of bone scan index","volume":"3","author":"Kaboteh","year":"2013","journal-title":"EJNMMI Res"},{"key":"10.1053\/j.semnuclmed.2023.07.004_bib0034","first-page":"408","article-title":"Breast cancer: Role of SPECT and PET in imaging bone metastases in Seminars in nuclear medicine","volume":"39","author":"Ben-Haim","year":"2009","journal-title":"Elsevier: WB Saunders; Philadelphia, Pennsylvania"},{"key":"10.1053\/j.semnuclmed.2023.07.004_bib0035","first-page":"431","article-title":"Multislice SPECT\/CT in benign and malignant bone disease: When the ordinary turns into the extraordinary in Seminars in nuclear medicine","volume":"39","author":"Gnanasegaran","year":"2009","journal-title":"Elsevier: WB Saunders, Philadelphia, Pennsylvania"},{"key":"10.1053\/j.semnuclmed.2023.07.004_bib0036","first-page":"286","article-title":"The role of single-photon emission computed tomography\/computed tomography in benign and malignant bone disease in Seminars in nuclear medicine","volume":"36","author":"Horger","year":"2006","journal-title":"Elsevier: WB Saunders; Philadelphia, Pennsylvania"},{"key":"10.1053\/j.semnuclmed.2023.07.004_bib0037","first-page":"253","article-title":"Effectiveness of quantitative bone SPECT\/CT for bone metastasis diagnosis","volume":"25","author":"Ikeda","year":"2022","journal-title":"Hell J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2023.07.004_bib0038","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s40644-020-00333-y","article-title":"Does whole-body bone SPECT\/CT provide additional diagnostic information over [18F]-FCH PET\/CT for the detection of bone metastases in the setting of prostate cancer biochemical recurrence?","volume":"20","author":"de Leiris","year":"2020","journal-title":"Cancer Imaging"},{"key":"10.1053\/j.semnuclmed.2023.07.004_bib0039","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1016\/S1470-2045(22)00642-8","article-title":"Intra-individual comparison of (18)F-sodium fluoride PET-CT and (99m)Tc bone scintigraphy with SPECT in patients with prostate cancer or breast cancer at high risk for skeletal metastases (MITNEC-A1): A multicentre, phase 3 trial","volume":"23","author":"B\u00e9nard","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1053\/j.semnuclmed.2023.07.004_bib0040","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1007\/s00259-016-3435-0","article-title":"Comparison of bone scintigraphy and 68 Ga-PSMA PET for skeletal staging in prostate cancer","volume":"43","author":"Pyka","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2023.07.004_bib0041","doi-asserted-by":"crossref","DOI":"10.3390\/molecules27092617","article-title":"A review on the current state and future perspectives of [(99m)Tc]Tc-housed PSMA-I in prostate cancer","volume":"27","author":"Brunello","year":"2022","journal-title":"Molecules"},{"key":"10.1053\/j.semnuclmed.2023.07.004_bib0042","doi-asserted-by":"crossref","first-page":"15993","DOI":"10.1038\/s41598-022-20280-x","article-title":"Head-to-head comparison of (99m)Tc-PSMA and (99m)Tc-MDP SPECT\/CT in diagnosing prostate cancer bone metastasis: A prospective, comparative imaging trial","volume":"12","author":"Zhang","year":"2022","journal-title":"Sci Rep"},{"key":"10.1053\/j.semnuclmed.2023.07.004_bib0043","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1097\/RLU.0000000000003702","article-title":"Comparing 99mTc-PSMA to 99mTc-MDP in prostate cancer staging of the skeletal system","volume":"46","author":"Kabunda","year":"2021","journal-title":"Clin Nucl Med"},{"key":"10.1053\/j.semnuclmed.2023.07.004_bib0044","first-page":"1","article-title":"Direct comparison of (99m)Tc-PSMA SPECT\/CT and (68)Ga-PSMA PET\/CT in patients with prostate cancer","volume":"8","author":"Albalooshi","year":"2020","journal-title":"Asia Ocean J Nucl Med Biol"},{"key":"10.1053\/j.semnuclmed.2023.07.004_bib0045","doi-asserted-by":"crossref","first-page":"e68","DOI":"10.1097\/RLU.0000000000003410","article-title":"99mTc-PSMA SPECT\/CT Versus 68Ga-PSMA PET\/CT in the evaluation of metastatic prostate cancer","volume":"46","author":"Fallahi","year":"2021","journal-title":"Clin Nucl Med"},{"key":"10.1053\/j.semnuclmed.2023.07.004_bib0046","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1002\/pros.24538","article-title":"An Australian experience using Tc-PSMA SPECT\/CT in the primary diagnosis of prostate cancer and for staging at biochemical recurrence after local therapy","volume":"83","author":"Duncan","year":"2023","journal-title":"Prostate"},{"key":"10.1053\/j.semnuclmed.2023.07.004_bib0047","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.2967\/jnumed.122.265252","article-title":"Delayed imaging improves lesion detectability in [(99m)Tc]Tc-PSMA-I&S SPECT\/CT in recurrent prostate cancer","volume":"64","author":"Berliner","year":"2023","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2023.07.004_bib0048","first-page":"27","article-title":"[(99m)Tc]Tc-PSMA-T4-Novel SPECT Tracer for metastatic PCa: From bench to clinic","volume":"21","author":"Maurin","year":"2022","journal-title":"Molecules"},{"key":"10.1053\/j.semnuclmed.2023.07.004_bib0049","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1007\/s00259-022-06028-9","article-title":"EANM practice guideline for quantitative SPECT-CT","volume":"50","author":"Dickson","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2023.07.004_bib0050","doi-asserted-by":"crossref","first-page":"83","DOI":"10.2967\/jnumed.112.111476","article-title":"An evidence-based review of quantitative SPECT imaging and potential clinical applications","volume":"54","author":"Bailey","year":"2013","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2023.07.004_bib0051","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1007\/s12350-017-0841-z","article-title":"First assessment of simultaneous dual isotope (123?I\/?99m Tc) cardiac SPECT on two different CZT cameras: A phantom study","volume":"25","author":"Blaire","year":"2018","journal-title":"J Nucl Cardiol"},{"key":"10.1053\/j.semnuclmed.2023.07.004_bib0052","first-page":"132","article-title":"Quantitative Tc-MDP SPECT\/CT as an alternative to 18 F-NaF PET\/CT for objective assessment of osteoblastic bone metastases","volume":"25","author":"Coskun","year":"2022","journal-title":"Hell J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2023.07.004_bib0053","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12891-019-3001-6","article-title":"Quantitative bone SPECT\/CT: High specificity for identification of prostate cancer bone metastases","volume":"20","author":"Tabotta","year":"2019","journal-title":"BMC Musculoskelet Disord"},{"key":"10.1053\/j.semnuclmed.2023.07.004_bib0054","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13550-016-0217-4","article-title":"Longitudinal analysis of bone metabolism using SPECT\/CT and 99m Tc-diphosphono-propanedicarboxylic acid: Comparison of visual and quantitative analysis","volume":"6","author":"Beck","year":"2016","journal-title":"EJNMMI Res"},{"key":"10.1053\/j.semnuclmed.2023.07.004_bib0055","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s41824-017-0006-y","article-title":"Skeletal standardized uptake values obtained by quantitative SPECT\/CT as an osteoblastic biomarker for the discrimination of active bone metastasis in prostate cancer","volume":"1","author":"Kuji","year":"2017","journal-title":"Eur J Hybrid Imaging"},{"key":"10.1053\/j.semnuclmed.2023.07.004_bib0056","doi-asserted-by":"crossref","first-page":"2925","DOI":"10.1007\/s00259-021-05189-3","article-title":"Performance of [68 Ga] Ga-PSMA-11?PET\/?CT in patients with recurrent prostate cancer after prostatectomy: A multi-centre evaluation of 2533 patients","volume":"48","author":"Afshar-Oromieh","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2023.07.004_bib0057","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1007\/s00259-012-2298-2","article-title":"PET imaging with a [68 Ga] gallium-labelled PSMA ligand for the diagnosis of prostate cancer: Biodistribution in humans and first evaluation of tumour lesions","volume":"40","author":"Afshar-Oromieh","year":"2013","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2023.07.004_bib0058","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/s12149-021-01602-x","article-title":"High detection rate in [18 F] PSMA-1007 PET: Interim results focusing on biochemical recurrence in prostate cancer patients","volume":"35","author":"Watabe","year":"2021","journal-title":"Ann Nucl Med"},{"key":"10.1053\/j.semnuclmed.2023.07.004_bib0059","doi-asserted-by":"crossref","first-page":"4231","DOI":"10.21037\/tau-21-912","article-title":"Systematic review & meta-analysis of positron emission tomography\/computed tomography and bone scan in the diagnosis of prostate lesions","volume":"10","author":"Wang","year":"2021","journal-title":"Transl Androl Urol"},{"key":"10.1053\/j.semnuclmed.2023.07.004_bib0060","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1111\/cpf.12480","article-title":"68Ga-PSMA PET\/CT for the detection of bone metastases in prostate cancer: A systematic review of the published literature","volume":"38","author":"Zacho","year":"2018","journal-title":"Clin Physiol Funct Imaging"},{"key":"10.1053\/j.semnuclmed.2023.07.004_bib0061","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1007\/s00330-017-4994-6","article-title":"Comparison of hybrid 68 Ga-PSMA-PET\/CT and 99m Tc-DPD-SPECT\/CT for the detection of bone metastases in prostate cancer patients: Additional value of morphologic information from low dose CT","volume":"28","author":"Janssen","year":"2018","journal-title":"Eur Radiol"},{"key":"10.1053\/j.semnuclmed.2023.07.004_bib0062","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1007\/s00330-018-5682-x","article-title":"68Ga-PSMA-PET\/CT in comparison with 18F-fluoride-PET\/CT and whole-body MRI for the detection of bone metastases in patients with prostate cancer: A prospective diagnostic accuracy study","volume":"29","author":"Dyrberg","year":"2019","journal-title":"Eur Radiol"},{"key":"10.1053\/j.semnuclmed.2023.07.004_bib0063","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1007\/s00259-018-4058-4","article-title":"Prospective comparison of 68Ga-PSMA PET\/CT, 18F-sodium fluoride PET\/CT and diffusion weighted-MRI at for the detection of bone metastases in biochemically recurrent prostate cancer","volume":"45","author":"Zacho","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2023.07.004_bib0064","first-page":"106","article-title":"Accuracy of 68Ga-PSMA-11?PET\/?CT and multiparametric MRI for the detection of local tumor and lymph node metastases in early biochemical recurrence of prostate cancer","volume":"10","author":"Radzina","year":"2020","journal-title":"Am J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2023.07.004_bib0065","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1097\/MNM.0000000000001637","article-title":"Hybrid Ga-68 prostate-specific membrane antigen PET\/MRI in the detection of skeletal metastasis in patients with newly diagnosed prostate cancer: Contribution of each part to the diagnostic performance","volume":"44","author":"Asa","year":"2022","journal-title":"Nucl Med Commun"},{"key":"10.1053\/j.semnuclmed.2023.07.004_bib0066","first-page":"1977","article-title":"A retrospective comparative study of sodium fluoride Na18F-PET\/CT and 68Ga-PSMA-11 PET\/CT in the bone metastases of prostate cancer using a volumetric 3-D radiomic analysis","volume":"12","author":"Kairemo","year":"2022","journal-title":"Life (Basel)"},{"key":"10.1053\/j.semnuclmed.2023.07.004_bib0067","article-title":"Comparison of PET\/CT and MRI in the diagnosis of bone metastasis in prostate cancer patients: A network analysis of diagnostic studies","volume":"11","author":"Liu","year":"2021","journal-title":"Front Oncol"},{"key":"10.1053\/j.semnuclmed.2023.07.004_bib0068","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s41824-022-00127-4","article-title":"Comparison of 68Ga-PSMA PET\/CT with fluoride PET\/CT for detection of bone metastatic disease in prostate cancer","volume":"6","author":"Regula","year":"2022","journal-title":"Eur J Hybrid Imaging"},{"key":"10.1053\/j.semnuclmed.2023.07.004_bib0069","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1007\/s11307-009-0217-0","article-title":"The use of F-18 choline PET in the assessment of bone metastases in prostate cancer: Correlation with morphological changes on CT","volume":"11","author":"Beheshti","year":"2009","journal-title":"Mol Imaging Biol"},{"key":"10.1053\/j.semnuclmed.2023.07.004_bib0070","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.apradiso.2012.06.034","article-title":"Comparison of Gallium-68 and Fluorine-18 imaging characteristics in positron emission tomography","volume":"76","author":"Sanchez-Crespo","year":"2013","journal-title":"Appl Radiat Isot"},{"key":"10.1053\/j.semnuclmed.2023.07.004_bib0071","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1007\/s00259-021-05616-5","article-title":"68Ga-PSMA PET in prostate cancer: A systematic review and meta-analysis of the observer agreement","volume":"49","author":"Chavoshi","year":"2022","journal-title":"Eur Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2023.07.004_bib0072","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1016\/j.crad.2017.06.116","article-title":"Early 68GA-PSMA PET\/MRI acquisition: Assessment of lesion detectability and PET metrics in patients with prostate cancer undergoing same-day late PET\/CT","volume":"72","author":"Domachevsky","year":"2017","journal-title":"Clin Radiol"},{"key":"10.1053\/j.semnuclmed.2023.07.004_bib0073","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1007\/s00259-017-3797-y","article-title":"Prospective head-to-head comparison of 11 C-choline-PET\/MR and 11 C-choline-PET\/CT for restaging of biochemical recurrent prostate cancer","volume":"44","author":"Eiber","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2023.07.004_bib0074","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1007\/s00259-015-3206-3","article-title":"Comparison of hybrid 68Ga-PSMA PET\/MRI and 68Ga-PSMA PET\/CT in the evaluation of lymph node and bone metastases of prostate cancer","volume":"43","author":"Freitag","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2023.07.004_bib0075","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/s41391-022-00581-y","article-title":"Head-to-head comparison of (68)Ga-PSMA-11 PET\/CT and (68)Ga-PSMA-11 PET\/MRI in the detection of biochemical recurrence of prostate cancer: Summary of head-to-head comparison studies","volume":"26","author":"Huo","year":"2023","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1053\/j.semnuclmed.2023.07.004_bib0076","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1007\/s00259-020-05025-0","article-title":"PET\/MRI in prostate cancer: A systematic review and meta-analysis","volume":"48","author":"Evangelista","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2023.07.004_bib0077","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20210728","article-title":"Prostate-specific membrane antigen (PSMA) fusion imaging in prostate cancer: PET\u2013CT vs PET\u2013MRI","volume":"95","author":"Liu","year":"2022","journal-title":"Br J Radiol"},{"key":"10.1053\/j.semnuclmed.2023.07.004_bib0078","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.2967\/jnumed.117.204677","article-title":"68Ga-PSMA-HBED-CC uptake in cervical, celiac, and sacral ganglia as an important pitfall in prostate cancer PET imaging","volume":"59","author":"Rischpler","year":"2018","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2023.07.004_bib0079","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14153768","article-title":"Clinical Applications of PSMA PET examination in patients with prostate cancer","volume":"14","author":"Rasul","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1053\/j.semnuclmed.2023.07.004_bib0080","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1111\/bju.15152","article-title":"Solitary rib lesions showing prostate-specific membrane antigen (PSMA) uptake in pre-treatment staging 68Ga-PSMA-11 positron emission tomography scans for men with prostate cancer: Benign or malignant?","volume":"126","author":"Chen","year":"2020","journal-title":"BJU Int"},{"key":"10.1053\/j.semnuclmed.2023.07.004_bib0081","doi-asserted-by":"crossref","first-page":"855","DOI":"10.2967\/jnumed.121.262989","article-title":"18F-DCFPyL PET acquisition, interpretation, and reporting: Suggestions after Food and drug administration approval","volume":"63","author":"Song","year":"2022","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2023.07.004_bib0082","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/S0140-6736(20)30314-7","article-title":"Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): A prospective, randomised, multicentre study","volume":"395","author":"Hofman","year":"2020","journal-title":"Lancet"},{"key":"10.1053\/j.semnuclmed.2023.07.004_bib0083","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.2967\/jnumed.112.104661","article-title":"Biodistribution, tumor detection, and radiation dosimetry of 18F-DCFBC, a low-molecular-weight inhibitor of prostate-specific membrane antigen, in patients with metastatic prostate cancer","volume":"53","author":"Cho","year":"2012","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2023.07.004_bib0084","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s00259-020-04782-2","article-title":"18 F-DCFPyL PET\/CT for primary staging in 160 high-risk prostate cancer patients; metastasis detection rate, influence on clinical management and preliminary results of treatment efficacy","volume":"48","author":"Wondergem","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2023.07.004_bib0085","doi-asserted-by":"crossref","first-page":"51","DOI":"10.2967\/jnumed.119.229187","article-title":"Matched-pair comparison of 68Ga-PSMA-11?PET\/?CT and 18F-PSMA-1007 PET\/CT: Frequency of pitfalls and detection efficacy in biochemical recurrence after radical prostatectomy","volume":"61","author":"Rauscher","year":"2020","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2023.07.004_bib0086","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7150\/thno.37894","article-title":"18F-labeled, PSMA-targeted radiotracers: Leveraging the advantages of radiofluorination for prostate cancer molecular imaging","volume":"10","author":"Werner","year":"2020","journal-title":"Theranostics"},{"key":"10.1053\/j.semnuclmed.2023.07.004_bib0087","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1007\/s00259-016-3573-4","article-title":"F-18 labelled PSMA-1007: Biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients","volume":"44","author":"Giesel","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2023.07.004_bib0088","first-page":"1","article-title":"Comparing the clinical performance and cost efficacy of [68 Ga] Ga-PSMA-11 and [18 F] PSMA-1007 in the diagnosis of recurrent prostate cancer: A Markov chain decision analysis","author":"Alberts","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2023.07.004_bib0089","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.euo.2020.06.012","volume":"4","author":"Anttinen","year":"2021","journal-title":"Eur Urol Oncol"},{"key":"10.1053\/j.semnuclmed.2023.07.004_bib0090","doi-asserted-by":"crossref","first-page":"4483","DOI":"10.1007\/s00259-021-05424-x","article-title":"Focal unspecific bone uptake on [18 F]-PSMA-1007 PET: A multicenter retrospective evaluation of the distribution, frequency, and quantitative parameters of a potential pitfall in prostate cancer imaging","volume":"48","author":"Gr\u00fcnig","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2023.07.004_bib0091","doi-asserted-by":"crossref","first-page":"729","DOI":"10.2967\/jnumed.119.234898","article-title":"Intraindividual comparison of 18F-PSMA-1007 with renally excreted PSMA ligands for PSMA PET imaging in patients with relapsed prostate cancer","volume":"61","author":"Dietlein","year":"2020","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2023.07.004_bib0092","doi-asserted-by":"crossref","first-page":"738","DOI":"10.2967\/jnumed.118.215434","article-title":"Unspecific 18F-PSMA-1007 bone uptake evaluated through PSMA-11 PET, bone scanning, and MRI triple validation in patients with biochemical recurrence of prostate cancer","volume":"64","author":"Seifert","year":"2023","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2023.07.004_bib0093","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1097\/JU.0000000000001698","article-title":"A phase 2\/3 prospective multicenter study of the diagnostic accuracy of prostate specific membrane antigen PET\/CT with 18F-DCFPyL in prostate cancer patients (OSPREY)","volume":"206","author":"Pienta","year":"2021","journal-title":"J Urol"},{"key":"10.1053\/j.semnuclmed.2023.07.004_bib0094","first-page":"1","article-title":"Comparison of PSMA-based (18)F-DCFPyL PET\/CT and Tc-99m MDP bone scan in detection of bone metastasis in prostate cancer","volume":"13","author":"Wilson","year":"2023","journal-title":"Am J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2023.07.004_bib0095","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s11307-016-0957-6","article-title":"PSMA-based [18 F] DCFPyL PET\/CT is superior to conventional imaging for lesion detection in patients with metastatic prostate cancer","volume":"18","author":"Rowe","year":"2016","journal-title":"Mol Imaging Biol"},{"key":"10.1053\/j.semnuclmed.2023.07.004_bib0096","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/s11307-015-0850-8","article-title":"Initial evaluation of [18 F] DCFPyL for prostate-specific membrane antigen (PSMA)-targeted PET imaging of prostate cancer","volume":"17","author":"Szabo","year":"2015","journal-title":"Mol Imaging Biol"},{"key":"10.1053\/j.semnuclmed.2023.07.004_bib0097","doi-asserted-by":"crossref","first-page":"183","DOI":"10.2967\/jnumed.119.227793","article-title":"Prospective comparison of PET imaging with PSMA-targeted 18F-DCFPyL versus Na18F for bone lesion detection in patients with metastatic prostate cancer","volume":"61","author":"Rowe","year":"2020","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2023.07.004_bib0098","first-page":"166","article-title":"Comparison of PSMA-based 18F-DCFPyL PET\/CT and pelvic multiparametric MRI for lesion detection in the pelvis in patients with prostate cancer","volume":"12","author":"Nguyen","year":"2022","journal-title":"Am J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2023.07.004_bib0099","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.2967\/jnumed.120.258574","article-title":"Matched-pair comparison of 18F-DCFPyL PET\/CT and 18F-PSMA-1007?PET\/?CT in 240 prostate cancer patients: Interreader agreement and lesion detection rate of suspected lesions","volume":"62","author":"Wondergem","year":"2021","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2023.07.004_bib0100","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.3390\/diagnostics13061175","article-title":"Preliminary findings of the role of FAPi in prostate cancer theranostics","volume":"13","author":"Laudicella","year":"2023","journal-title":"Diagnostics (Basel)"},{"key":"10.1053\/j.semnuclmed.2023.07.004_bib0101","doi-asserted-by":"crossref","first-page":"160","DOI":"10.2967\/jnumed.120.244806","article-title":"The latest developments in imaging of fibroblast activation protein","volume":"62","author":"Altmann","year":"2021","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2023.07.004_bib0102","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s41181-019-0069-0","article-title":"Targeting of activated fibroblasts for imaging and therapy","volume":"4","author":"Lindner","year":"2019","journal-title":"EJNMMI Radiopharm Chem"},{"key":"10.1053\/j.semnuclmed.2023.07.004_bib0103","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.1007\/s00259-022-05706-y","article-title":"Clinical summary of fibroblast activation protein inhibitor-based radiopharmaceuticals: Cancer and beyond","volume":"49","author":"Li","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2023.07.004_bib0104","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1002\/prca.201300095","article-title":"Understanding fibroblast activation protein (FAP): Substrates, activities, expression and targeting for cancer therapy","volume":"8","author":"Hamson","year":"2014","journal-title":"Proteomics Clin Appl"},{"key":"10.1053\/j.semnuclmed.2023.07.004_bib0105","doi-asserted-by":"crossref","first-page":"61","DOI":"10.3390\/cancers10030061","article-title":"Teaming up for trouble: Cancer cells, transforming growth factor-\u03b21 signaling and the epigenetic corruption of stromal na\u00efve fibroblasts","volume":"10","author":"Lamprecht","year":"2018","journal-title":"Cancers (Basel)"},{"key":"10.1053\/j.semnuclmed.2023.07.004_bib0106","doi-asserted-by":"crossref","first-page":"4887","DOI":"10.1038\/s41388-019-0765-y","article-title":"Biological heterogeneity and versatility of cancer-associated fibroblasts in the tumor microenvironment","volume":"38","author":"Bu","year":"2019","journal-title":"Oncogene"},{"key":"10.1053\/j.semnuclmed.2023.07.004_bib0107","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.ejphar.2017.05.022","article-title":"Effects of the fibroblast activation protein inhibitor, PT100, in a murine model of pulmonary fibrosis","volume":"809","author":"Egger","year":"2017","journal-title":"Eur J Pharmacol"},{"key":"10.1053\/j.semnuclmed.2023.07.004_bib0108","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1111\/jth.12396","article-title":"Increased N-terminal cleavage of alpha-2-antiplasmin in patients with liver cirrhosis","volume":"11","author":"De Willige","year":"2013","journal-title":"J Thromb Haemost"},{"key":"10.1053\/j.semnuclmed.2023.07.004_bib0109","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.3390\/ph15081000","article-title":"From Automated synthesis to in vivo application in multiple types of cancer: Clinical results with [68Ga] Ga-DATA5m","volume":"15","author":"Greifenstein","year":"2022","journal-title":"SA. FAPi. Pharmaceuticals"},{"key":"10.1053\/j.semnuclmed.2023.07.004_bib0110","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s00259-021-05423-y","article-title":"High fibroblast-activation-protein expression in castration-resistant prostate cancer supports the use of FAPI-molecular theranostics","volume":"49","author":"Kesch","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2023.07.004_bib0111","doi-asserted-by":"crossref","first-page":"801","DOI":"10.2967\/jnumed.119.227967","article-title":"68Ga-FAPI PET\/CT: Tracer uptake in 28 different kinds of cancer","volume":"60","author":"Kratochwil","year":"2019","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2023.07.004_bib0112","article-title":"Comparison of the relative diagnostic performance of [68Ga] Ga-DOTA-FAPI-04 and [18F] FDG PET\/CT for the detection of bone metastasis in patients with different cancers","volume":"11","author":"Wu","year":"2021","journal-title":"Front Oncol"},{"key":"10.1053\/j.semnuclmed.2023.07.004_bib0113","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s40644-022-00481-3","article-title":"The use of advanced imaging in guiding the further investigation and treatment of primary prostate cancer","volume":"22","author":"Duan","year":"2022","journal-title":"Cancer Imaging"},{"key":"10.1053\/j.semnuclmed.2023.07.004_bib0114","doi-asserted-by":"crossref","first-page":"33","DOI":"10.3390\/radiation1010004","article-title":"Biodistribution and radiation dosimetric analysis of [68Ga] Ga-RM2: A potent GRPR antagonist in prostate carcinoma patients","volume":"1","author":"Haendeler","year":"2020","journal-title":"Radiation"},{"key":"10.1053\/j.semnuclmed.2023.07.004_bib0115","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1002\/pros.21434","article-title":"Profiling gastrin-releasing peptide receptor in prostate tissues: Clinical implications and molecular correlates","volume":"72","author":"Beer","year":"2012","journal-title":"Prostate"},{"key":"10.1053\/j.semnuclmed.2023.07.004_bib0116","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.2967\/jnumed.120.259630","article-title":"PSMA- and GRPR-Targeted PET: Results from 50 patients with biochemically recurrent prostate cancer","volume":"62","author":"Baratto","year":"2021","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2023.07.004_bib0117","doi-asserted-by":"crossref","first-page":"557","DOI":"10.2967\/jnumed.115.168393","article-title":"Pilot comparison of (6)(8)Ga-RM2 PET and (6)(8)Ga-PSMA-11 PET in patients with biochemically recurrent prostate cancer","volume":"57","author":"Minamimoto","year":"2016","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2023.07.004_bib0118","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1007\/s00330-022-08982-2","article-title":"Value of 68Ga-labeled bombesin antagonist (RM2) in the detection of primary prostate cancer comparing with [18F]fluoromethylcholine PET\/CT and mpMRI: A phase I\/II study","volume":"33","author":"Beheshti","year":"2023","journal-title":"Eur Radiol"},{"key":"10.1053\/j.semnuclmed.2023.07.004_bib0119","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.2967\/jnumed.122.263971","article-title":"Correlation of (68)Ga-RM2 PET with postsurgery histopathology findings in patients with newly diagnosed intermediate- or high-risk prostate cancer","volume":"63","author":"Duan","year":"2022","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2023.07.004_bib0120","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.2967\/jnumed.120.259630","article-title":"PSMA-and GRPR-targeted PET: Results from 50 patients with biochemically recurrent prostate cancer","volume":"62","author":"Baratto","year":"2021","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2023.07.004_bib0121","doi-asserted-by":"crossref","first-page":"803","DOI":"10.2967\/jnumed.117.197624","article-title":"Prospective evaluation of (68)Ga-RM2 PET\/MRI in patients with biochemical recurrence of prostate cancer and negative findings on conventional imaging","volume":"59","author":"Minamimoto","year":"2018","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2023.07.004_bib0122","first-page":"e882","article-title":"The Role of 68Ga-PSMA- and 68Ga-DOTA-RM2 PET\/MRI in the primary staging of high-risk prostate cancer patients undergoing radical prostatectomy","volume":"207","author":"Cucchiara","year":"2022","journal-title":"Preliminary results of a prospective, single center study"},{"key":"10.1053\/j.semnuclmed.2023.07.004_bib0123","doi-asserted-by":"crossref","first-page":"334","DOI":"10.3390\/cancers14020334","article-title":"(68)Ga-PSMA and (68)Ga-DOTA-RM2 PET\/MRI in recurrent prostate cancer: Diagnostic performance and association with clinical and histopathological data","volume":"14","author":"Mapelli","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1053\/j.semnuclmed.2023.07.004_bib0124","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.3390\/diagnostics11112068","article-title":"Preliminary results of an ongoing prospective clinical trial on the use of (68)Ga-PSMA and (68)Ga-DOTA-RM2 PET\/MRI in staging of high-risk prostate cancer patients","volume":"11","author":"Mapelli","year":"2021","journal-title":"Diagnostics (Basel)"},{"key":"10.1053\/j.semnuclmed.2023.07.004_bib0125","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/BF00252034","article-title":"Skeletal uptake of diphosphonate: A review","volume":"5","author":"Fogelman","year":"1980","journal-title":"Eur J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2023.07.004_bib0126","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1088\/0143-0815\/7\/4\/003","article-title":"The single-passage extraction of 18F in rabbit bone","volume":"7","author":"Wootton","year":"1986","journal-title":"Clin Phys Physiol Meas"},{"key":"10.1053\/j.semnuclmed.2023.07.004_bib0127","doi-asserted-by":"crossref","first-page":"68","DOI":"10.2967\/jnumed.106.037200","article-title":"Skeletal PET with 18F-fluoride: Applying new technology to an old tracer","volume":"49","author":"Grant","year":"2008","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2023.07.004_bib0128","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1007\/s00259-015-3138-y","article-title":"(18)F-NaF PET\/CT: EANM procedure guidelines for bone imaging","volume":"42","author":"Beheshti","year":"2015","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2023.07.004_bib0129","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1111\/bju.12599","article-title":"Spine metastases in prostate cancer: Comparison of technetium-99m-MDP whole-body bone scintigraphy, [(18) F]choline positron emission tomography(PET)\/computed tomography (CT) and [(18) F]NaF PET\/CT","volume":"114","author":"Poulsen","year":"2014","journal-title":"BJU Int"},{"key":"10.1053\/j.semnuclmed.2023.07.004_bib0130","first-page":"6","article-title":"More advantages in detecting bone and soft tissue metastases 18 from prostate cancer using F-PSMA PET\/CT","volume":"22","author":"Pianou","year":"2019","journal-title":"Hell J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2023.07.004_bib0131","doi-asserted-by":"crossref","first-page":"55S","DOI":"10.2967\/jnumed.115.169730","article-title":"Evaluation of prostate cancer bone metastases with 18F-NaF and 18F-fluorocholine PET\/CT","volume":"57","author":"Beheshti","year":"2016","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2023.07.004_bib0132","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s12149-019-01343-y","article-title":"18F-NaF-PET\/CT for the detection of bone metastasis in prostate cancer: A meta-analysis of diagnostic accuracy studies","volume":"33","author":"Sheikhbahaei","year":"2019","journal-title":"Annals of Nuclear Medicine"},{"key":"10.1053\/j.semnuclmed.2023.07.004_bib0133","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1097\/MNM.0000000000001621","article-title":"Bone metastases in prostate cancer\u2013Gallium-68\u2013labeled prostate-specific membrane antigen or Fluorine 18 sodium fluoride PET\/computed tomography\u2013the better tracer?","volume":"43","author":"Agrawal","year":"2022","journal-title":"Nucl Med Commun"},{"key":"10.1053\/j.semnuclmed.2023.07.004_bib0134","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1007\/s00259-018-4048-6","article-title":"Comparison of [(68)Ga]Ga-PSMA-11 PET\/CT with [(18)F]NaF PET\/CT in the evaluation of bone metastases in metastatic prostate cancer patients prior to radionuclide therapy","volume":"45","author":"Uprimny","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2023.07.004_bib0135","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s11307-019-01392-9","article-title":"Simultaneous PET\/MRI in the evaluation of breast and prostate cancer using combined Na[18F] F and [18F]FDG: A focus on skeletal lesions","volume":"22","author":"Sonni","year":"2020","journal-title":"Mol Imaging Biol"},{"key":"10.1053\/j.semnuclmed.2023.07.004_bib0136","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s40658-022-00513-8","article-title":"Quantitative [(99m)Tc]Tc-MDP SPECT\/CT correlated with [(18)F]NaF PET\/CT for bone metastases in patients with prostate cancer","volume":"9","author":"Tanaka","year":"2022","journal-title":"EJNMMI Phys"},{"key":"10.1053\/j.semnuclmed.2023.07.004_bib0137","doi-asserted-by":"crossref","first-page":"217","DOI":"10.2967\/jnmt.116.176859","article-title":"The role of 18F-sodium fluoride PET\/CT bone scans in the diagnosis of metastatic bone disease from breast and prostate cancer","volume":"44","author":"Kulshrestha","year":"2016","journal-title":"J Nucl Med Technol"},{"key":"10.1053\/j.semnuclmed.2023.07.004_bib0138","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1148\/rg.345130061","article-title":"Newer PET application with an old tracer: Role of 18F-NaF skeletal PET\/CT in oncologic practice","volume":"34","author":"Bastawrous","year":"2014","journal-title":"Radiographics"},{"key":"10.1053\/j.semnuclmed.2023.07.004_bib0139","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1111\/iju.14992","article-title":"Evaluation of 11C-choline positron emission tomography\/computed tomography for determining treatment response in castration-resistant prostate cancer patients","volume":"29","author":"Kimura","year":"2022","journal-title":"Int J Urol"},{"key":"10.1053\/j.semnuclmed.2023.07.004_bib0140","first-page":"990","article-title":"PET imaging of prostate cancer using carbon-11-choline","volume":"39","author":"Hara","year":"1998","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2023.07.004_bib0141","first-page":"1040","article-title":"Utility of choline positron emission tomography\/computed tomography for lymph node involvement identification in intermediate-to high-risk prostate cancer: A systematic literature review and meta-analysis","volume":"63","author":"Evangelista","year":"2013","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2023.07.004_bib0142","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1007\/s00256-014-1903-9","article-title":"Comparison of choline-PET\/CT, MRI, SPECT, and bone scintigraphy in the diagnosis of bone metastases in patients with prostate cancer: A meta-analysis","volume":"43","author":"Shen","year":"2014","journal-title":"Skeletal Radiol"},{"key":"10.1053\/j.semnuclmed.2023.07.004_bib0143","article-title":"Diagnostic performance of choline PET\/CT for the detection of bone metastasis in prostate cancer: A systematic review and meta-analysis","volume":"13","author":"Guo","year":"2018","journal-title":"Skeletal Radiol"},{"key":"10.1053\/j.semnuclmed.2023.07.004_bib0144","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1160\/nukmed-0075","article-title":"Comparison of 11C-choline-PET\/CT and whole body-MRI for staging of prostate cancer","volume":"46","author":"Eschmann","year":"2007","journal-title":"Nuklearmedizin"},{"key":"10.1053\/j.semnuclmed.2023.07.004_bib0145","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1007\/s12094-016-1563-4","article-title":"Whole-body diffusion-weighted magnetic resonance imaging (WB-DW-MRI) vs choline-positron emission tomography-computed tomography (choline-PET\/CT) for selecting treatments in recurrent prostate cancer","volume":"19","author":"Conde-Moreno","year":"2017","journal-title":"Clin Transl Oncol"},{"key":"10.1053\/j.semnuclmed.2023.07.004_bib0146","first-page":"119","article-title":"18F-Fluoromethylcholine-positron emission tomography\/computed tomography for diagnosing bone and lymph node metastases in patients with intermediate-or high-risk prostate cancer","volume":"7","author":"Mortensen","year":"2019","journal-title":"Clin Transl Oncol"},{"key":"10.1053\/j.semnuclmed.2023.07.004_bib0147","doi-asserted-by":"crossref","first-page":"345","DOI":"10.3109\/21681805.2015.1005665","volume":"49","author":"Evangelista","year":"2015","journal-title":"Scand J Urol"},{"key":"10.1053\/j.semnuclmed.2023.07.004_bib0148","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1007\/s00259-013-2467-y","article-title":"Comparison of integrated whole-body [11C]choline PET\/MR with PET\/CT in patients with prostate cancer","volume":"40","author":"Souvatzoglou","year":"2013","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2023.07.004_bib0149","doi-asserted-by":"crossref","first-page":"117","DOI":"10.3390\/diagnostics11010117","article-title":"Nuclear imaging for bone metastases in prostate cancer: The emergence of modern techniques using novel radiotracers","volume":"11","author":"Luining","year":"2021","journal-title":"Diagnostics (Basel)"},{"key":"10.1053\/j.semnuclmed.2023.07.004_bib0150","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s00259-013-2525-5","article-title":"Comparison of PET imaging with a 68 Ga-labelled PSMA ligand and 18 F-choline-based PET\/CT for the diagnosis of recurrent prostate cancer","volume":"41","author":"Afshar-Oromieh","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2023.07.004_bib0151","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1007\/s00259-016-3490-6","article-title":"Comparison of 68 Ga-labelled PSMA-11 and 11 C-choline in the detection of prostate cancer metastases by PET\/CT","volume":"44","author":"Schwenck","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2023.07.004_bib0152","first-page":"46","article-title":"A preliminary study of anti-1-amino-3-18F-fluorocyclobutyl-1-carboxylic acid for the detection of prostate cancer","volume":"48","author":"Oka","year":"2007","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2023.07.004_bib0153","first-page":"254","article-title":"Amino acid transporters ASCT2 and LAT1 in cancer: Partners in crime? in Seminars in cancer biology","volume":"15","author":"Fuchs","year":"2005","journal-title":"Elsevier: Academic Press; Cambridge, Massachusetts"},{"key":"10.1053\/j.semnuclmed.2023.07.004_bib0154","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/j.nucmedbio.2015.07.005","article-title":"[14C] fluciclovine (alias anti-[14C] FACBC) uptake and ASCT2 expression in castration-resistant prostate cancer cells","volume":"42","author":"Ono","year":"2015","journal-title":"Nucl Med Biol"},{"key":"10.1053\/j.semnuclmed.2023.07.004_bib0155","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.3389\/fonc.2019.01438","article-title":"Diagnostic performance of PET\/CT using 18F-FACBC in prostate cancer: A meta-analysis","volume":"9","author":"Bin","year":"2020","journal-title":"Front Oncol"},{"key":"10.1053\/j.semnuclmed.2023.07.004_bib0156","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1097\/MNM.0000000000001051","article-title":"Comparison of 18F-Fluciclovine PET\/CT and 99mTc-MDP bone scan in detection of bone metastasis in prostate cancer","volume":"40","author":"Chen","year":"2019","journal-title":"Nucl Med Commun"},{"key":"10.1053\/j.semnuclmed.2023.07.004_bib0157","doi-asserted-by":"crossref","first-page":"e226","DOI":"10.1097\/RLU.0000000000002130","article-title":"Diagnostic performance of 18F-fluciclovine in detection of prostate cancer bone metastases","volume":"43","author":"Chen","year":"2018","journal-title":"Clin Nucl Med"},{"key":"10.1053\/j.semnuclmed.2023.07.004_bib0158","doi-asserted-by":"crossref","first-page":"733","DOI":"10.2967\/jnumed.117.204032","article-title":"Update on 18F-fluciclovine PET for prostate cancer imaging","volume":"59","author":"Parent","year":"2018","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2023.07.004_bib0159","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/s41391-017-0007-8","article-title":"The use of PET\/CT in prostate cancer","volume":"21","author":"Li","year":"2018","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1053\/j.semnuclmed.2023.07.004_bib0160","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.2967\/jnumed.114.143628","article-title":"Anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid: Physiologic uptake patterns, incidental findings, and variants that may simulate disease","volume":"55","author":"Schuster","year":"2014","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2023.07.004_bib0161","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/S0090-4295(00)00896-7","article-title":"Fluorodeoxyglucose positron emission tomography studies in diagnosis and staging of clinically organ-confined prostate cancer","volume":"57","author":"Liu","year":"2001","journal-title":"Urology"},{"key":"10.1053\/j.semnuclmed.2023.07.004_bib0162","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000019923","article-title":"Fluorine-18-fluorodeoxyglucose positron emission tomography is useless for the detection of local recurrence after radical prostatectomy","volume":"36","author":"Hofer","year":"1999","journal-title":"Eur Urol"},{"key":"10.1053\/j.semnuclmed.2023.07.004_bib0163","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1007\/s00259-005-1842-8","article-title":"Pitfalls of FDG-PET for the diagnosis of osteoblastic bone metastases in patients with breast cancer","volume":"32","author":"Nakai","year":"2005","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2023.07.004_bib0164","doi-asserted-by":"crossref","first-page":"81","DOI":"10.2967\/jnumed.110.077941","article-title":"Prostate cancer: PET with 18F-FDG, 18F-or 11C-acetate, and 18F-or 11C-choline","volume":"52","author":"Jadvar","year":"2011","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2023.07.004_bib0165","first-page":"735","article-title":"A comparison of (18)F-DCFPyL, (18)F-NaF, and (18)F-FDG PET\/CT in a prospective cohort of men with metastatic prostate cancer","volume":"63","author":"Fourquet","year":"2022","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2023.07.004_bib0166","doi-asserted-by":"crossref","first-page":"31","DOI":"10.3390\/cancers12010031","article-title":"Role of baseline and post-therapy 18F-FDG PET in the prognostic stratification of metastatic castration-resistant prostate cancer (mCRPC) patients treated with radium-223","volume":"12","author":"Bauckneht","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1053\/j.semnuclmed.2023.07.004_bib0167","doi-asserted-by":"crossref","first-page":"301","DOI":"10.5489\/cuaj.7107","article-title":"(18)F-fluorodeoxyglucose positron emission tomography\/computed tomography (PET\/CT) is accurate for high-grade prostate cancer bone staging when compared to bone scintigraphy","volume":"15","author":"Otis-Chapados","year":"2021","journal-title":"Can Urol Assoc J"},{"key":"10.1053\/j.semnuclmed.2023.07.004_bib0168","first-page":"613","article-title":"Flare on [18F] PSMA-1007?PET\/?CT after short-term androgen deprivation therapy and its correlation to FDG uptake: Possible marker of tumor aggressiveness in treatment-na\u00efve metastatic prostate cancer patients","volume":"50","author":"Malaspina","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1053\/j.semnuclmed.2023.07.004_bib0169","first-page":"242","article-title":"Detection of the prostate cancer bone metastases: Is it feasible to compare 18F-fluorocholine PET\/CT, 18F-fluorodeoxyglucose PET\/CT and 99mTc\u2013methyl diphosphonate bone scintigraphy?","volume":"15","author":"Pietrzak","year":"2018","journal-title":"Cancers (Basel)"},{"key":"10.1053\/j.semnuclmed.2023.07.004_bib0170","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1148\/radiol.2015151169","article-title":"Radiomics: Images are more than pictures, they are data","volume":"278","author":"Gillies","year":"2016","journal-title":"Radiology"},{"key":"10.1053\/j.semnuclmed.2023.07.004_bib0171","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s13139-018-0514-0","article-title":"Radiomics and deep learning in clinical imaging: What should we do?","volume":"52","author":"Choi","year":"2018","journal-title":"Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2023.07.004_bib0172","doi-asserted-by":"crossref","first-page":"R150","DOI":"10.1088\/0031-9155\/61\/13\/R150","article-title":"Applications and limitations of radiomics","volume":"61","author":"Yip","year":"2016","journal-title":"Phys Med Biol"},{"key":"10.1053\/j.semnuclmed.2023.07.004_bib0173","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.771787","article-title":"Radiomics for identification and prediction in metastatic prostate cancer: A review of studies","volume":"11","author":"Kendrick","year":"2021","journal-title":"Front Oncol"},{"key":"10.1053\/j.semnuclmed.2023.07.004_bib0174","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.1007\/s00259-019-04593-0","article-title":"Artificial intelligence and radiomics in nuclear medicine: Potentials and challenges","volume":"46","author":"Aktolun","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2023.07.004_bib0175","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.gltp.2021.01.004","article-title":"Machine learning and deep learning applications-a vision","volume":"2","author":"Sharma","year":"2021","journal-title":"Glob Transit Proc"},{"key":"10.1053\/j.semnuclmed.2023.07.004_bib0176","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1109\/TMI.2016.2528162","article-title":"Deep convolutional neural networks for computer-aided detection: CNN architectures, dataset characteristics and transfer learning","volume":"35","author":"Shin","year":"2016","journal-title":"IEEE Trans Med Imaging"},{"key":"10.1053\/j.semnuclmed.2023.07.004_bib0177","doi-asserted-by":"crossref","first-page":"89","DOI":"10.2174\/1573405616666200528153453","article-title":"Study of the usefulness of bone scan index calculated from 99m-technetium-hydroxymethylene diphosphonate (99mTc-HMDP) bone scintigraphy for bone metastases from prostate cancer using deep learning algorithms","volume":"17","author":"Higashiyama","year":"2021","journal-title":"Curr Med Imaging"},{"key":"10.1053\/j.semnuclmed.2023.07.004_bib0178","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s00259-021-05481-2","article-title":"Diagnostic performance of deep learning models for detecting bone metastasis on whole-body bone scan in prostate cancer","volume":"49","author":"Han","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2023.07.004_bib0179","doi-asserted-by":"crossref","first-page":"17046","DOI":"10.1038\/s41598-020-74135-4","article-title":"Deep neural network based artificial intelligence assisted diagnosis of bone scintigraphy for cancer bone metastasis","volume":"10","author":"Zhao","year":"2020","journal-title":"Sci Rep"},{"key":"10.1053\/j.semnuclmed.2023.07.004_bib0180","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0237213","article-title":"Bone metastasis classification using whole body images from prostate cancer patients based on convolutional neural networks application","volume":"15","author":"Papandrianos","year":"2020","journal-title":"PLoS One"},{"key":"10.1053\/j.semnuclmed.2023.07.004_bib0181","doi-asserted-by":"crossref","first-page":"685","DOI":"10.3390\/diagnostics13040685","article-title":"Artificial intelligence of object detection in skeletal scintigraphy for automatic detection and annotation of bone metastases","volume":"13","author":"Liao","year":"2023","journal-title":"Diagnostics (Basel)"},{"key":"10.1053\/j.semnuclmed.2023.07.004_bib0182","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.3390\/jpm11121248","article-title":"Detection of bone metastases on bone scans through image classification with contrastive learning","volume":"11","author":"Hsieh","year":"2021","journal-title":"J Pers Med"},{"key":"10.1053\/j.semnuclmed.2023.07.004_bib0183","doi-asserted-by":"crossref","first-page":"493","DOI":"10.3390\/healthcare8040493","article-title":"A lightweight convolutional neural network architecture applied for bone metastasis classification in nuclear medicine: A case study on prostate cancer patients","volume":"8","author":"Ntakolia","year":"2020","journal-title":"Healthcare (Basel)"},{"key":"10.1053\/j.semnuclmed.2023.07.004_bib0184","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s41747-022-00282-0","article-title":"Radiomics and artificial intelligence in prostate cancer: New tools for molecular hybrid imaging and theragnostics","volume":"6","author":"Liberini","year":"2022","journal-title":"Eur Radiol Exp"},{"key":"10.1053\/j.semnuclmed.2023.07.004_bib0185","first-page":"1","article-title":"Automated quantification of PET\/CT skeletal tumor burden in prostate cancer using artificial intelligence: The PET index","author":"Lindgren Belal","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2023.07.004_bib0186","doi-asserted-by":"crossref","first-page":"225019","DOI":"10.1088\/1361-6560\/aaebd0","article-title":"Automated classification of benign and malignant lesions in 18F-NaF PET\/CT images using machine learning","volume":"63","author":"Perk","year":"2018","journal-title":"Phys Med Biol"},{"key":"10.1053\/j.semnuclmed.2023.07.004_bib0187","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s00259-019-04606-y","article-title":"Deep neural network for automatic characterization of lesions on 68Ga-PSMA-11 PET\/CT","volume":"47","author":"Zhao","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2023.07.004_bib0188","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1007\/s00330-021-08245-6","article-title":"Radiomics for detecting prostate cancer bone metastases invisible in CT: a proof-of-concept study","volume":"32","author":"Hinzpeter","year":"2022","journal-title":"Eur Radiol"},{"key":"10.1053\/j.semnuclmed.2023.07.004_bib0189","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20190286","article-title":"Machine learning for differentiating metastatic and completely responded sclerotic bone lesion in prostate cancer: A retrospective radiomics study","volume":"92","author":"Acar","year":"2019","journal-title":"Br J Radiol"},{"key":"10.1053\/j.semnuclmed.2023.07.004_bib0190","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1007\/s00259-020-05140-y","article-title":"Supervised machine learning enables non-invasive lesion characterization in primary prostate cancer with [(68)Ga]Ga-PSMA-11 PET\/MRI","volume":"48","author":"Papp","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2023.07.004_bib0191","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1007\/s00259-020-04971-z","article-title":"Machine learning-based analysis of [(18)F]DCFPyL PET radiomics for risk stratification in primary prostate cancer","volume":"48","author":"Cysouw","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2023.07.004_bib0192","doi-asserted-by":"crossref","first-page":"622","DOI":"10.3390\/diagnostics10090622","article-title":"Machine learning facilitates hotspot classification in PSMA-PET\/CT with nuclear medicine specialist accuracy","volume":"10","author":"Moazemi","year":"2020","journal-title":"Diagnostics (Basel)"},{"key":"10.1053\/j.semnuclmed.2023.07.004_bib0193","doi-asserted-by":"crossref","first-page":"186","DOI":"10.3390\/diagnostics11020186","article-title":"Estimating the potential of radiomics features and radiomics signature from pretherapeutic PSMA-PET-CT scans and clinical data for prediction of overall survival when treated with (177)Lu-PSMA","volume":"11","author":"Moazemi","year":"2021","journal-title":"Diagnostics (Basel)"},{"key":"10.1053\/j.semnuclmed.2023.07.004_bib0194","first-page":"395","article-title":"Diagnostic scope of (18)F-PSMA-1007 PET\/CT: Comparison with multiparametric MRI and bone scintigraphy for the assessment of early prostate cancer recurrence","volume":"11","author":"Saule","year":"2021","journal-title":"Am J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2023.07.004_bib0195","first-page":"354","article-title":"State of the art of PET\/CT with 11-choline and 18F-fluorocholine in the diagnosis and follow-up of localized and locally advanced prostate cancer","volume":"68","author":"Vagnoni","year":"2015","journal-title":"Arch Esp Urol"}],"container-title":["Seminars in Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001299823000570?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001299823000570?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T22:42:31Z","timestamp":1757544151000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0001299823000570"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":195,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["S0001299823000570"],"URL":"https:\/\/doi.org\/10.1053\/j.semnuclmed.2023.07.004","relation":{},"ISSN":["0001-2998"],"issn-type":[{"value":"0001-2998","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bone Metastasis in Prostate Cancer: Bone Scan Versus PET Imaging","name":"articletitle","label":"Article Title"},{"value":"Seminars in Nuclear Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.semnuclmed.2023.07.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}